ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Anti-HER2 Antibody-drug Conjugate IBI354

Its studies are mostly in Fallopian Tube Neoplasms · Breast Neoplasms, led by Innovent Biologics.

Drug pageAnti-HER2 Antibody-drug Conjugate IBI354: every studyAll 4 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Feb 5, 20253 company-led studies, 3 open or runningNext primary completion: Dec 28, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Innovent Biologics33 open or runningphase 3since Feb 5, 2025Nov 23, 2022Dec 28, 2027phase 3 · NCT06834672

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 23, 2022First study: phase 2 study in Locally Advanced Unresectable or Metastatic Solid TumorsFirst studyNCT05636215 · 368 planned · Australia, China
  2. Feb 5, 2025Phase 3 study in Fallopian Tube NeoplasmsNCT06834672 · 450 enrolled · China
  3. Jan 15, 2026Phase 3 study in HER2-positive Breast CancerNCT07377643 · 540 planned · China

Ahead

  1. Dec 28, 2027Primary completion: phase 3 study in Fallopian Tube NeoplasmsNCT06834672
  2. Apr 28, 2028Primary completion: phase 3 study in HER2-positive Breast CancerNCT07377643

TargetBeta

ERBB2 →read by rule
“An antibody-drug conjugate (ADC) composed of a monoclonal antibody directed against the tumor-associated antigen (TAA) human epidermal growth factor receptor 2 (EGFR2; HER2; ErbB2) ”NCIt, by rule

Other programs on ERBB2

ProgramCompanyFurthest phaseStudies
TrastuzumabruleHoffmann-La Rochephase 485
pertuzumabruleHoffmann-La Rochephase 456
trastuzumab deruxtecanruleDaiichi Sankyophase 449
tucatinibrulePfizerphase 425
disitamab vedotinRemeGenphase 336
trastuzumab rezetecanruleJiangsu HengRui Medicinephase 336
Lutetium-177Novartisphase 324
trastuzumab brengitecanSichuan Biokin Pharmaceuticalphase 321
Gallium-68Philogenphase 317
zongertinibruleBoehringer Ingelheimphase 315
Anti-HER2/Topoisomerase I Inhibitor ADC TQB2102Sino Biopharmaceuticalphase 313
sunvozertinibruleDizal Pharmaceuticalsphase 312

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07377643HER2-positive Breast Cancer · China3RecruitingApr 28, 2028540
NCT06834672Fallopian Tube Neoplasms · China3Active, not recruitingDec 28, 2027450
NCT05636215Locally Advanced Unresectable or Metastatic Solid Tumors · Australia, China2RecruitingApr 30, 2025368

How it is read

Names in the registry

  • “IBI354”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.